Who are DDAVP Inhalant Product's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): desmopressin MELT formulation, terlipressin (vasoconstrictor), desmopressin tablet, Terlipressin & then Dummy, Terlipressin and Noradrenaline, Terlipressin Injectable Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ddavp-inhalant-product.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

DDAVP Inhalant Product — Competitive Intelligence Brief

DDAVP Inhalant Product (DDAVP Inhalant Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasopressin analog; antidiuretic agent. Area: Endocrinology; Hematology.

marketed Vasopressin analog; antidiuretic agent V2 vasopressin receptor; V1 vasopressin receptor Endocrinology; Hematology Small molecule Live · refreshed every 30 min

Target snapshot

DDAVP Inhalant Product (DDAVP Inhalant Product) — Nationwide Children's Hospital. DDAVP (desmopressin) is a synthetic vasopressin analog that acts as an antidiuretic hormone (ADH) replacement, increasing water reabsorption in the kidneys and promoting von Willebrand factor and factor VIII release from endothelial cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DDAVP Inhalant Product TARGET	DDAVP Inhalant Product	Nationwide Children's Hospital	marketed	Vasopressin analog; antidiuretic agent	V2 vasopressin receptor; V1 vasopressin receptor
desmopressin MELT formulation	desmopressin MELT formulation	University Hospital, Ghent	marketed	Vasopressin analog / Antidiuretic agent	V2 vasopressin receptor
terlipressin (vasoconstrictor)	terlipressin (vasoconstrictor)	National Science and Technology Council, Taiwan	marketed	Vasopressin analog	Vasopressin V1 receptor
desmopressin tablet	desmopressin tablet	University Hospital, Ghent	marketed	Vasopressin analog; antidiuretic agent	V2 vasopressin receptor
Terlipressin & then Dummy	Terlipressin & then Dummy	Aga Khan University	marketed	Vasopressin analog	Vasopressin V1 receptor
Terlipressin and Noradrenaline	Terlipressin and Noradrenaline	Post Graduate Institute of Medical Education and Research, Chandigarh	phase 3	Vasopressin analogue and catecholamine	V1A receptor and alpha-adrenergic receptor
Terlipressin Injectable Product	Terlipressin Injectable Product	Aga Khan University	phase 3	Vasopressin analogue	V2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasopressin analog; antidiuretic agent class)

Nationwide Children's Hospital · 1 drug in this class
University Hospital, Ghent · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DDAVP Inhalant Product — Competitive Intelligence Brief. https://druglandscape.com/ci/ddavp-inhalant-product. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab